WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 205996

CAS#: 261944-52-9

Description: T900607 is a pentafluorophenylsulfonamide compound with potential antineoplastic activity. T900607 inhibits tubulin polymerization by binding irreversibly to colchicine binding sites, resulting in cell cycle arrest and apoptosis.

Price and Availability




T900607 is not in stock, but may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 205996
Name: T900607
CAS#: 261944-52-9
Chemical Formula: C14H10F5N3O4S
Exact Mass: 411.03122
Molecular Weight: 411.3
Elemental Analysis: C, 40.88; H, 2.45; F, 23.10; N, 10.22; O, 15.56; S, 7.80

Synonym: T900607, T-900607, T 900607, T607; T-607, T 607

IUPAC/Chemical Name: N-(4-Methoxy-3-ureidophenyl)-2,3,4,5,6-pentafluorobenzenesulfonamide


InChi Code: InChI=1S/C14H10F5N3O4S/c1-26-7-3-2-5(4-6(7)21-14(20)23)22-27(24,25)13-11(18)9(16)8(15)10(17)12(13)19/h2-4,22H,1H3,(H3,20,21,23)

SMILES Code: O=S(C1=C(F)C(F)=C(F)C(F)=C1F)(NC2=CC=C(OC)C(NC(N)=O)=C2)=O

Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO, not in water

Shelf Life:
>5 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:


 1: Gelmon KA, Belanger K, Soulieres D, Britten C, Chia S, Charpentier D, Chi K, Powers J, Walsh W, Seymour L. A phase I study of T900607 given once every 3 weeks in patients with advanced refractory cancers; National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) IND 130. Invest New Drugs. 2005 Oct;23(5):445-53. PubMed PMID: 16133796.